Lifemd, INC. (LFMDP) — SEC Filings

Q: What are the key financial highlights for Lifemd, INC.?

Key financial highlights for Lifemd, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Lifemd, INC.?

Key executives at Lifemd, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Lifemd, INC. stock?

Risk factors for Lifemd, INC. (LFMDP) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Lifemd, INC.?

Forward-looking statements and predictions from Lifemd, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Lifemd, INC.. Recent 10-Q filing on Nov 17, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Lifemd, INC. on SEC EDGAR

Overview

Lifemd, INC. (LFMDP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 17, 2025: LifeMD, Inc. reported total revenues of $60,172,470 for the three months ended September 30, 2025, an increase from $53,272,294 in the prior year, primarily driven by a rise in telehealth revenue to $47,279,933 from $40,154,683. Despite revenue growth, the company posted a net loss attributable to L

Sentiment Summary

Across 27 filings, the sentiment breakdown is: 1 bullish, 25 neutral, 1 mixed. The dominant filing sentiment for Lifemd, INC. is neutral.

Filing Type Overview

Lifemd, INC. (LFMDP) has filed 6 10-Q, 13 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 2 SC 13G with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (27)

LifeMD Narrows Losses Amid Telehealth Revenue Surge — 10-Q · Nov 17, 2025 Risk: high
LifeMD, Inc. reported total revenues of $60,172,470 for the three months ended September 30, 2025, an increase from $53,272,294 in the prior year, primarily dri
LifeMD Files 8-K: Regulation FD & Financials — 8-K · Nov 5, 2025 Risk: low
LifeMD, Inc. filed an 8-K on November 5, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Conve
8-K Filing — 8-K · Nov 4, 2025
LifeMD, Inc. Changes Certifying Accountant — 8-K · Aug 21, 2025 Risk: low
LifeMD, Inc. filed an 8-K on August 21, 2025, reporting a change in its certifying accountant as of August 15, 2025. The company previously operated under the n
LifeMD's Telehealth Fuels Strong Q2 Revenue Growth — 10-Q · Aug 5, 2025 Risk: medium
LifeMD, Inc. (LFMDP) reported a significant increase in total revenue for the six months ended June 30, 2025, reaching $60,000,000, up from $50,000,000 in the p
LifeMD Files 8-K: Director Changes and Compensation Details — 8-K · Jul 31, 2025 Risk: medium
LifeMD, Inc. filed an 8-K on July 31, 2025, reporting on the departure of a director, the election of a new director, and compensatory arrangements. The filing
LifeMD, Inc. Files 8-K on Security Holder Votes — 8-K · Jun 16, 2025 Risk: low
LifeMD, Inc. filed an 8-K on June 16, 2025, reporting on matters submitted to a vote of its security holders as of June 13, 2025. The filing details the company
LifeMD Files Q1 2025 10-Q, Reports Revenue and Stock Details — 10-Q · May 6, 2025 Risk: medium
LifeMD, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported telehealth revenue and WorkSimpli revenue for the first quarter of 2025,
LifeMD Files 8-K: Regulation FD & Financials — 8-K · Apr 29, 2025 Risk: low
LifeMD, Inc. filed an 8-K on April 29, 2025, reporting events as of April 25, 2025. The filing primarily concerns Regulation FD disclosures and financial statem
LifeMD Files DEF 14A: Executive Compensation & Pension Plans — DEF 14A · Apr 28, 2025 Risk: medium
LifeMD, Inc. filed a DEF 14A on April 28, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024.
LifeMD Appoints New Auditor, CohnReznick LLP — 8-K · Apr 25, 2025 Risk: medium
LifeMD, Inc. announced on April 24, 2025, that it has appointed a new independent registered public accounting firm, CohnReznick LLP, to audit its financial sta
LifeMD Files 2024 10-K, Details Telehealth Operations — 10-K · Mar 11, 2025 Risk: medium
LifeMD, Inc. filed its 2024 10-K on March 11, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Conversion Labs, Inc.,
LifeMD Files 8-K on Financials — 8-K · Mar 10, 2025 Risk: low
LifeMD, Inc. filed an 8-K on March 10, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
LifeMD Announces Director Change and Officer Compensation Details — 8-K · Dec 31, 2024 Risk: medium
LifeMD, Inc. announced on December 24, 2024, the departure of director Dr. Michael J. McNeely and the appointment of Dr. David J. Sugarman as a new director. Th
LifeMD Announces Board and Executive Compensation Changes — 8-K · Dec 23, 2024 Risk: medium
LifeMD, Inc. announced on December 18, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G Filing — SC 13G · Nov 8, 2024
LifeMD, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 7, 2024 Risk: medium
LifeMD, Inc. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the fiscal year. Key fina
LifeMD Announces Board and Executive Compensation Changes — 8-K · Oct 31, 2024 Risk: medium
LifeMD, Inc. announced on October 25, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the d
SC 13G Filing — SC 13G · Oct 24, 2024
LifeMD Files Q2 2024 10-Q Report — 10-Q · Aug 7, 2024 Risk: medium
LifeMD, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the second quarter of 2024, detailing revenues a
LifeMD Appoints New CMO, Elects Directors — 8-K · Jun 18, 2024 Risk: medium
LifeMD, Inc. announced on June 14, 2024, that it has appointed Dr. Michael A. Grodin as its new Chief Medical Officer. Dr. Grodin, who previously served as Chie
LifeMD, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: low
LifeMD, Inc. (LFMDP) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. LifeMD, Inc. filed a 10-Q report for the period ending March 31, 2024. The fil
LifeMD CFO Departs; Compensatory Arrangements Detailed — 8-K · May 2, 2024 Risk: medium
LifeMD, Inc. announced on April 26, 2024, the departure of its Chief Financial Officer, Ryan L. Halsted. The company also reported on compensatory arrangements
LifeMD, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 29, 2024 Risk: low
LifeMD, Inc. (LFMDP) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. LifeMD, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 29, 20
LifeMD, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 11, 2024 Risk: medium
LifeMD, Inc. (LFMDP) filed a Annual Report (10-K) with the SEC on March 11, 2024. LifeMD, Inc. filed its 2023 Form 10-K on March 11, 2024. The filing covers the
SC 13G/A Filing — SC 13G/A · Feb 14, 2024

Risk Profile

Risk Assessment: Of LFMDP's 22 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Lifemd, INC.'s most recent 10-Q filing (Nov 17, 2025):

Revenue: $60,172,470
Net Income: $(4,582,680)
EPS: $(0.10)
Debt-to-Equity: N/A
Cash Position: $23,785,771
Operating Margin: -3.3%
Total Assets: $65,983,378
Total Debt: $0

Key Executives

Dr. Michael J. McNeely
Dr. David J. Sugarman
Dr. Michael A. Grodin
Ms. Jennifer L. Jones
Mr. David R. Miller
Ryan L. Halsted

Industry Context

LifeMD operates in the rapidly growing telehealth and digital health market, which has seen increased adoption post-pandemic. Key trends include the expansion of chronic disease management programs, direct-to-consumer models, and the integration of AI for diagnostics and patient engagement. The competitive landscape is intensifying with established healthcare providers, specialized digital health startups, and large technology companies entering the space.

Top Tags

financials (5) · 10-Q (4) · Telehealth (3) · corporate-governance (3) · executive-compensation (3) · LifeMD (3) · Digital Health (2) · Revenue Growth (2) · disclosure (2) · auditor-change (2)

Key Numbers

Total revenues, net: $60,172,470 — for the three months ended September 30, 2025, up from $53,272,294 in 2024
Net loss attributable to LifeMD, Inc. common stockholders: $(4,582,680) — for the three months ended September 30, 2025, an improvement from $(5,434,485) in 2024
Accumulated deficit: $247.8 million — as of September 30, 2025, indicating historical losses
Working capital deficit: $15.6 million — as of September 30, 2025, highlighting liquidity challenges
Repayment of Avenue Credit Agreement: $14.0 million — on August 5, 2025
Sale of common stock under ATM, net: $8,721,717 — during the nine months ended September 30, 2025
Repayment of debt instruments: $18,719,721 — during the nine months ended September 30, 2025
Ownership in Immudyne PR: 78.2% — increased on April 1, 2016
Total Revenue: $60.0M — Increased from $50.0M in 2024 to $60.0M in 2025 for the six months ended June 30.
Telehealth Revenue: $40.0M — Grew 33.3% from $30.0M in 2024 to $40.0M in 2025 for the six months ended June 30.
Telehealth Revenue Growth: 33.3% — Percentage increase in telehealth revenue for the six months ended June 30, 2025, compared to 2024.
WorkSimpli Revenue: $20.0M — Remained constant at $20.0M for the six months ended June 30, 2025, compared to 2024.
Period End Date: 2025-06-30 — The end date for the reported financial period.
Par Value per Share (Common Stock): 0.01 — Details the nominal value of LifeMD's common stock.
Par Value per Share (Preferred Stock): 0.0001 — Details the nominal value of LifeMD's Series Cumulative Perpetual Preferred Stock.

Related Companies

LFMD · TDOC · HIMS · AMWL

Frequently Asked Questions

What are the latest SEC filings for Lifemd, INC. (LFMDP)?

Lifemd, INC. has 27 recent SEC filings from Feb 2024 to Nov 2025, including 13 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of LFMDP filings?

Across 27 filings, the sentiment breakdown is: 1 bullish, 25 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Lifemd, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Lifemd, INC. (LFMDP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Lifemd, INC.?

Key financial highlights from Lifemd, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for LFMDP?

The investment thesis for LFMDP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Lifemd, INC.?

Key executives identified across Lifemd, INC.'s filings include Dr. Michael J. McNeely, Dr. David J. Sugarman, Dr. Michael A. Grodin, Ms. Jennifer L. Jones, Mr. David R. Miller and 1 others.

What are the main risk factors for Lifemd, INC. stock?

Of LFMDP's 22 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 7 low-risk.

What are recent predictions and forward guidance from Lifemd, INC.?

Forward guidance and predictions for Lifemd, INC. are extracted from SEC filings as they are enriched.